Compares bone marrow cells in people with follicular lymphoma and people without blood disease
Compares bone marrow samples from adults with follicular lymphoma with control samples.
Plain-language title generated from the registry record
Registry title: MOLyF : Bone Marrow and Follicular Lymphoma
Key facts
- Where
- Rennes, FranceSee the site
Where in France
- CHU RennesRennes, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Rennes University Hospital
- Trial code
- NCT06608147
- Record updated
- 10 December 2024
- Original description
This is a prospective single-center study designed to assess potential differences in cell composition between bone marrows of patients with follicular lymphoma and those from control subjects.Read full original descriptionShow less
Bone Marrow and Follicular Lymphoma
This is a prospective single-center study designed to assess potential differences in cell composition between bone marrows of patients with follicular lymphoma and those from control subjects.
Follicular lymphoma is the most common indolent lymphoma. It is characterised by systematic relapses and bone marrow dissemination in 70% of patients at the time of diagnosis.
Although relapses are thought to be related to refractory tumour cells nested in a supportive microenvironment in the bone marrow, the mechanisms involved are poorly understood.
To study the specificities of the bone marrow of patients with follicular lymphoma, It is necessary to compare them with control samples.
This study takes advantage of surgeries involving sternotomies to recover lost bone marrow and establish a bone marrow bank of patients without hematological disease.
This bank will be used to set up control cohorts for other clinical trials involving patients with follicular lymphoma.
Inclusion: Major patient; Patient hospitalized in the thoracic, cardiac and vascular surgery department for surgery involving a sternotomy; Patient with free, informed, written consent; Patient covered by a health insurance scheme.
Exclusion: History of haematological malignancy or haemogram disturbance; Immunomodulating treatment: immunosuppressants, corticoids, antineoplastics; Persons covered by articles L. 1121-5 to L. 1121-8 and L. 1122-1-2 of the French Public Health Code (e.g. minors, protected adults, etc.)].